公开(公告)号：WO2015047982A3

公开(公告)日：2015-11-19

申请号：PCT/US2014056898

申请日：2014-09-23

Applicant: CHDI FOUNDATION INC

Inventor： DOMINGUEZ CELIA ,  TOLEDO-SHERMAN LETICIA M ,  PRIME MICHAEL ,  MITCHELL WILLIAM ,  WENT NAOMI

IPC: A61K31/381

CPC classification number: C07D413/12 ,  C07D209/08 ,  C07D213/46 ,  C07D215/18 ,  C07D217/02 ,  C07D231/56 ,  C07D235/08 ,  C07D237/28 ,  C07D239/74 ,  C07D241/42 ,  C07D261/20 ,  C07D263/56 ,  C07D277/24 ,  C07D277/64 ,  C07D307/79 ,  C07D319/18 ,  C07D333/06 ,  C07D333/10 ,  C07D333/28 ,  C07D407/12

Abstract: Certain compounds, or pharmaceutically acceptable salts or prodrugs thereof, are provided herein. Also provided are pharmaceutical compositions comprising at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of KMO activity are described, which comprise administering to such patients an amount of at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein effective to reduce signs or symptoms of the disease or disorder are disclosed. These diseases include neurodegenerative disorders such as Huntington's disease.

Abstract translation: 本文提供了某些化合物或其药学上可接受的盐或前药。 还提供了药物组合物，其包含至少一种本文所述的化合物或其药学上可接受的盐或前药和一种或多种药学上可接受的载体。 描述了治疗患有对抑制KMO活性有响应的某些疾病和病症的患者的方法，其包括向所述患者施用有效减少体征或症状的量的本文所述的至少一种化合物或其药学上可接受的盐或前药 披露了该疾病或病症。 这些疾病包括神经退行性疾病，如亨廷顿病。